Database : MEDLINE
Search on : Polydipsia [Words]
References found : 2849 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 285 go to page                         

  1 / 2849 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29518762
[Au] Autor:Trimpou P; Olsson DS; Ehn O; Ragnarsson O
[Ad] Address:Department of Endocrinology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
[Ti] Title:Diagnostic value of the water deprivation test in the polyuria-polydipsia syndrome.
[So] Source:Hormones (Athens);16(4):414-422, 2017 Oct.
[Is] ISSN:1109-3099
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Diabetes insipidus (DI) and primary polydipsia (PP) are characterised by polyuria and polydipsia. It is crucial to differentiate between these two disorders since the treatment is different. The aim of this study was to evaluate the diagnostic value of the short and an extended variant of the water deprivation test (WDT) and of measuring urinary vasopressin (AVP) in patients with polyuria and polydipsia. DESIGN: A retrospective, single-centre study based on WDTs performed between 2004 and 2014 including 104 consecutive patients with the polyuria-polydipsia syndrome. During a strict water deprivation, weight, urinary osmolality, urinary vasopressin and specific gravity were collected until one of the following was reached: i) >3% weight reduction, ii) Urinary specific gravity >1.020 or, urinary osmolality >800 mOsm/L, iii) Intolerable adverse symptoms such as excessive thirst. RESULTS: Out of 104 patients (67 women, 37 men), 21 (20%) were diagnosed with DI and 83 (80%) with PP. The median (interquartile range; range) test duration was 14 hours (10-16; 3-36) in patients with DI and 18 hours (14-24; 7-48) in patients with PP (P=0.011). Of those diagnosed with PP, 22 (26%) did not reach urinary specific gravity >1.020 nor urine osmolality >800 mOsm/L. Urine AVP did not overlap between patients with PP and patients with central DI. CONCLUSIONS: The short WDT is of limited value in the diagnostic work-up of polydipsia and polyuria and a partial DI may have been missed in every fourth patient diagnosed with PP. Urinary AVP has excellent potential in discriminating PP from central DI.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.14310/horm.2002.1762

  2 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29220526
[Au] Autor:Zhao C; Tella SH; Del Rivero J; Kommalapati A; Ebenuwa I; Gulley J; Strauss J; Brownell I
[Ad] Address:Hematology Oncology Fellowship Program, National Institutes of Health, Bethesda, Maryland.
[Ti] Title:Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.
[So] Source:J Clin Endocrinol Metab;103(2):365-369, 2018 Feb 01.
[Is] ISSN:1945-7197
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Context: Immune checkpoint inhibitors, including anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-related adverse events (irAEs), which resemble autoimmune diseases. Anterior pituitary hypophysitis with secondary hypopituitarism is a frequently reported irAE, especially in patients receiving anti-CTLA4 treatment. In contrast, posterior pituitary involvement, such as central diabetes insipidus (DI), is relatively rare and is unreported in patients undergoing PD-1/PD-L1 blockade. Case Description: We describe a case of a 73-year-old man with Merkel cell carcinoma who received the anti-PD-L1 monoclonal antibody avelumab and achieved partial response. The patient developed nocturia, polydipsia, and polyuria 3 months after starting avelumab. Further laboratory testing revealed central DI. Avelumab was held and he received desmopressin for the management of central DI. Within 6 weeks after discontinuation of avelumab, the patient's symptoms resolved and he was eventually taken off desmopressin. The patient remained off avelumab and there were no signs or symptoms of DI 2 months after the discontinuation of desmopressin. Conclusion: To our knowledge, this is the first report of central DI associated with anti-PD-L1 immunotherapy. The patient's endocrinopathy was successfully managed by holding treatment with the immune checkpoint inhibitor. This case highlights the importance of early screening and appropriate management of hormonal irAEs in subjects undergoing treatment with immune checkpoint inhibitors to minimize morbidity and mortality.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1210/jc.2017-01905

  3 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29513157
[Au] Autor:Malerba E; Mazzarino M; Del Baldo F; Corradini S; Carotenuto G; Giunti M; Fracassi F
[Ad] Address:Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy.
[Ti] Title:Use of lispro insulin for treatment of diabetic ketoacidosis in cats.
[So] Source:J Feline Med Surg;:1098612X18761696, 2018 Mar 01.
[Is] ISSN:1532-2750
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives The aim of this study was to evaluate the efficacy and safety of lispro insulin for the treatment of feline diabetic ketoacidosis (DKA). Times to resolution of hyperglycaemia, ketosis and acidosis were compared between cats treated with continuous rate infusion (CRI) of lispro insulin and cats treated with CRI of regular insulin. Methods Client-owned cats with naturally occurring DKA, newly diagnosed with diabetes mellitus (DM) or already receiving treatment for DM, were included. Diagnosis of DKA involved the presence of at least two clinical signs consistent with DKA (eg, polyuria/polydipsia, anorexia, severe lethargy, vomiting and dehydration), blood glucose (BG) concentration >13.9 mmol/l (>250 mg/dl), blood beta hydroxybutyrate (BHB) concentration >2.5 mmol/l and venous pH <7.3 or bicarbonate <15 mEq/l. Cats were treated with a standard protocol of an intravenous (IV) CRI of regular insulin (group R) or lispro insulin (group L). The time to resolution of DKA was defined as the time interval from when the IV CRI of insulin began until marked hyperglycaemia (BG >13.9 mmol/l [>250 mg/dl]), ketosis (BHB concentration >1 mmol/l) and acidosis (venous pH <7.3 and/or bicarbonate <15 mEq/l) resolved. Results Eighteen DKA cases (nine per group) were enrolled into the study. There were no significant differences in the median time to resolution of three variables (hyperglycaemia, ketosis and acidosis) between the two groups. Two cats in group R developed hypoglycaemia during the CRI of insulin. One cat in group L and three cats in group R developed hypophosphataemia, which required phosphate supplementation. Conclusions and relevance IV CRI of lispro insulin has few side effects and appears to be as effective as IV CRI of regular insulin in the treatment of cats with DKA.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1177/1098612X18761696

  4 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29509141
[Au] Autor:Joller S; Stettler M; Locher I; Dettwiler M; Seefried F; Meylan M; Drögemüller C
[Ad] Address:Institut für Genetik, Vetsuisse-Fakultät, Universität Bern.
[Ti] Title:Fanconi-Bickel-Syndrom: eine bislang unerkannte Erbkrankheit beim Braunvieh. [Fanconi-Bickel-Syndrom: a novel genetic disease in Original Braunvieh].
[So] Source:Schweiz Arch Tierheilkd;160(3):179-184, 2018 Mar.
[Is] ISSN:0036-7281
[Cp] Country of publication:Switzerland
[La] Language:ger
[Ab] Abstract:INTRODUCTION: This case report describes a new genetic disease of the Braunvieh breed in Switzerland. The bovine disorder also occurs in German Fleckvieh, and corresponds to human Fanconi-Bickel syndrome which is an inherited glycogen storage disease caused by mutations of the SLC2A2 gene encoding the glucose transporter GLUT2. This case report describes a single affected Original Braunvieh calf genotyped as homozygous for the FH2-associated SLC2A2 frame shift mutation. The clinical examination showed stunted growth, polyuria and polydipsia, as well as poor claw horn and coat quality. Necropsy revealed a pale cortex of the kidneys and a unilateral renal hypoplasia. Histology showed tubulonephrosis of the proximal tubules with protein- and glucose-rich contents. Glycogen accumulation was not evident in any organ. This finding is different from the reported lesions in two previously described GLUT2-deficient Fleckvieh heifers. In the presented case, growth retardation mainly seems to be associated with renal dysfunction. A direct gene test is available to eliminate the mutant allele from the population.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:In-Data-Review
[do] DOI:10.17236/sat00152

  5 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29499256
[Au] Autor:Carpenter CP; Rawson A; Hains DS; Giel DW
[Ad] Address:Division of Pediatric Urology, Department of Urology, Le Bonheur Children's Hospital, The University of Tennessee Health Science Center, Memphis, TN. Electronic address: carpenter.christina@gmail.com.
[Ti] Title:Resolution of Diabetes Insipidus after Pyeloplasty: a Case Report and Review of the Literature.
[So] Source:Urology;, 2018 Feb 27.
[Is] ISSN:1527-9995
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Nephrogenic diabetes insipidus (NDI), a rare cause of polyuria and polydipsia in children, is usually managed with medications and careful monitoring of water intake. We present a child who was incidentally found to have right hydronephrosis secondary to ureteropelvic junction obstruction, and was subsequently also diagnosed with NDI. After being medically managed, he underwent open right pyeloplasty. His polydipsia abated within one month of surgery, and he has done well off of medications since that time. NDI resolution after correction of obstructive uropathy in adults has been reported, but this represents a novel case in pediatrics.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher

  6 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29491282
[Au] Autor:Nakamichi A; Ocho K; Oka K; Yasuda M; Hasegawa K; Iwamuro M; Obika M; Rai K; Otsuka F
[Ad] Address:Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
[Ti] Title:Manifestation of Central Diabetes Insipidus in a Patient with Thyroid Storm.
[So] Source:Intern Med;, 2018 Feb 28.
[Is] ISSN:1349-7235
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:We herein report a case of central diabetes insipidus complicated with thyroid storm. A middle-aged woman who was receiving treatment for Graves' disease suddenly complained of polydipsia, polyuria and general fatigue. Laboratory tests showed hyperthyroidism, hypernatremia, hypoosmolar urine and a decreased plasma vasopressin level. The occurrence of central diabetes insipidus with hyperthyroidism was revealed on the basis of pituitary magnetic resonance imaging, a water deprivation test and a desmopressin test. The clinical co-existence of diabetes insipidus and hyperthyroidism is very rare; however, the complication should be considered when hypernatremia and/or dehydration progress in patients with Graves's disease as a common autoimmune-related etiology.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:Publisher
[do] DOI:10.2169/internalmedicine.0063-17

  7 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29490124
[Au] Autor:Torosyan N; Spencer D; Penev S; Bota RG
[Ad] Address:Department of Psychiatry, UC Irvine Health Neuropsychiatric Center, University of California, Irvine, California, USA.
[Ti] Title:Psychogenic Polydipsia in a Woman With Anorexia Nervosa: Case Report and Recommendations.
[So] Source:Prim Care Companion CNS Disord;20(1), 2018 Feb 08.
[Is] ISSN:2155-7780
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:In-Data-Review

  8 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29464737
[Au] Autor:Tuli G; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
[Ad] Address:Department of Paediatric Endocrinology, Regina Margherita Children's Hospital, Department of Public Health and Paediatric Sciences, University of Turin.
[Ti] Title:Copeptin role in polyuria-polydipsia syndrome (PPS) differential diagnosis and reference range in paediatric age.
[So] Source:Clin Endocrinol (Oxf);, 2018 Feb 21.
[Is] ISSN:1365-2265
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: Plasma arginine-vasopressin (AVP) analysis can help in the differential diagnosis of the polyuria-polydipsia syndrome (PPS), even if such investigation is hampered by technical difficulties, conversely to its surrogate copeptin. This study aims to enlarge the existing data on normal copeptin levels in childhood, to evaluate the correlation between copeptin, serum sodium and plasma and urine osmolality, and to assess the utility of the copeptin analysis in the diagnostic work-up of PPS in the paediatric age. PATIENTS AND METHODS: Plasma copeptin levels were evaluated in 53 children without AVP disorders (control population), in 12 hypopituitaric children and in 15 patients with PPS after water deprivation test (WDT). RESULTS: Mean basal copeptin levels were 5.2±1.56 (range 2.4-8.6 pmol/L) in the control population, 2.61±0.49 pmol/L in the hypopituitaric children with complete diabetes insipidus (CDI) (p=0.04), and 6.21±1.17 pmol/L in the hypopituitaric patients without DI (p=0.02). After WDT, among 15 naïve polyuric/polydipsic children copeptin values greater than 20 pmol/liter allowed to identify nephrogenic diabetes insipidus (NDI), concentrations below 2.2 pmol/liter complete central DI (CCDI) and between 5-20 pmol/l primary polydipsia (PP). Copeptin cut-off level of 3.5 pmol/l distinguished CDI from PP, with a sensitivity and specificity of 75% and 83.3%, respectively. CONCLUSION: Copeptin evaluation holds promises as a diagnostic tool in paediatric PPS; its interpretation might be useful to promptly distinguish NDI, even avoiding the WDT need. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:Publisher
[do] DOI:10.1111/cen.13583

  9 / 2849 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29463074
[Au] Autor:Refardt J; Christ-Crain M
[Ad] Address:Clinic of Endocrinology, Diabetology and Metabolism University Hospital Basel, Basel, Switzerland.
[Ti] Title:Diabetes insipidus in pregnancy: how to advice the patient?
[So] Source:Minerva Endocrinol;, 2018 Feb 19.
[Is] ISSN:1827-1634
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Diabetes insipidus, characterized by polyuria and polydipsia, is a rare disease during pregnancy. Nevertheless, its recognition is important to avoid complications due to dehydration and hypernatremia. Its manifestation during pregnancy ranges from exacerbation of pre-existing central or nephrogenic diabetes insipidus to transient pregnancy-induced diabetes insipidus due to the increased metabolism of the antidiuretic hormone vasopressin by the placental vasopressinase. Diagnosis can be challenging, as urinary frequency is common during pregnancy and primary polydipsia also needs to be excluded. Also the standard water deprivation test is not recommended during pregnancy due to the increased risk of complications. Treatment depends upon the final diagnosis, with desmopressin (DDAVP) being the medication of choice in AVP-deficient diabetes insipidus, whereas nephrogenic diabetes insipidus requires treatment of the underlying disease and supportive measures.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:Publisher
[do] DOI:10.23736/S0391-1977.18.02807-9

  10 / 2849 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 29462536
[Au] Autor:Akande TO; Adeleye JO; Sepu N; Awofisoye OI
[Ti] Title:Type 1 diabetes mellitus and Graves' disease in Down's syndrome--a rare combination.
[So] Source:Afr J Med Med Sci;45(3):299-301, 2016 Sep.
[Is] ISSN:0309-3913
[Cp] Country of publication:Nigeria
[La] Language:eng
[Ab] Abstract:BACKGROUND: Autoimmune diseases including thyroid. disorders, type 1 diabetes and celiac disease are commoner in persons with Down's syndrome compared with the general population. Coexistent type 1 diabetes and hyperthyroidism in Down's syndrome is however not commonly reported in literature. OBJECTIVE: To report a case of a lady presenting with Graves' disease and type 1 diabetes at the same time. CLINICAL PRESENTATION: We report the case of a 22- year-old lady with Down's syndrome who presented with weight loss, polyuria and polydipsia. Physical examination revealed typical dysmorphicfacies of Down's syndrome and a goitre. Laboratory data revealed hyperglycaemia (random plasma glucose-331 mg/dl). She also had biochemical evidence in keeping with hyperthyroidism and markedly elevated thyroid peroxidase antibodies (>1087.0 IU/ml). She improved after rehydration, insulin therapy and antithyroid drugs. CONCLUSION: Coexisting autoimmune diseases may present in patients with Down's syndrome. We advocate for routine screening for diabetes and thyroid dysfunction in ersons with Down's syndrome.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:In-Process


page 1 of 285 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information